MR-PET fusion imaging in evaluating adnexal lesions: A preliminary study;Fusione RM/PET nelle lesioni annessiali: Studio preliminare

Radiologia Medica

Volumn 116, Issue 8, 2011, Pages 1288-1302

  Fiaschetti, V ^a   Calabria, F ^b   Crusco, S ^a   Meschini, A ^a   Nucera, F ^a   Schillaci, O ^a   Simonetti, G ^a  

^a TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

CT PET; Fusion imaging; Metabolic evaluation; MR PET; Ovarian lesions; Postprocessing

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADNEXA DISEASE; ADULT; AGED; ARTICLE; BIOPSY; COMPARATIVE STUDY; FEMALE; HUMAN; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; RETROSPECTIVE STUDY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

ADNEXAL DISEASES; ADULT; AGED; BIOPSY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 83655191993     PISSN: 00338362     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11547-011-0720-7     Document Type: Article

References (22)

1. American Cancer Society (1998) Cancer fact and figures. American cancer society 13
2. Morrow C, Cutin C, Paul M et al (1998) Synopsis of gynecologc oncology. Churchill Livingstone 13
3. N. Colombo T. Van Gorp G. Parma, et al. 2006 Ovarian cancer Crit Rev Oncol Hematol 60 159 179 17018256 10.1016/j.critrevonc.2006.03.004 (Pubitemid 44636248)
4. H.T. Lynch M.J. Casey C.L. Snyder, et al. 2009 Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management Mol Oncol 3 97 137 19383374 10.1016/j.molonc.2009.02.004 1:CAS:528: DC%2BC3cXjvFGisrw%3D
5. Ovarian Cancer. National Alliance (2011) http/www.ovariancancer.org. (Last access 05/2011)
6. FIGO Cancer Committee 1986 Staging announcement Gynecol Oncol 25 383 385 10.1016/0090-8258(86)90092-2
7. E. Bouic-Pagès H. Perrochia S. Mérigeaud, et al. 2009 MR Imaging of primary ovarian tumors with pathologic correlation Journal de Radiologie 90 787 802 19752784 10.1016/S0221-0363(09)73210-X
8. T. Kojima O. Ishiko T. Ichimura, et al. 2001 The usefulness and limits of magnetic resonance imaging in the differential diagnosis of pelvic tumors Oncol Rep 8 867 869 11410800 1:STN:280:DC%2BD3MzkslymsQ%3D%3D (Pubitemid 33758139)
9. R. Bar-Shalom A.Y. Valdivia M.D. Blaufox 2000 PET imaging in oncology Semin Nucl Med 30 150 185 10928381 10.1053/snuc.2000.7439 1:STN:280: DC%2BD3M%2FjvFWrtA%3D%3D (Pubitemid 30469914)
10. D. Grisaru B. Almog C. Levine, et al. 2004 The diagnostic accuracy of 18F-fluorodeoxyglucose PET/CT in patients with gynecological malignancies Gynecol Oncol 94 680 684 15350358 10.1016/j.ygyno.2004.05.053 (Pubitemid 39194460)
11. S.K. Stevens H. Hricak J.L. Stern 1991 Ovarian lesions: detection and characterization with gadolinium-enhanced MR imaging at 1.5 T Radiology 181 481 488 1924792 1:STN:280:DyaK38%2FitFGjsg%3D%3D
12. I. Imaoka A. Wada Y. Kaji, et al. 2006 Developing an MR imaging strategy for diagnosis of ovarian masses Radiographics 26 1431 1448 16973774 10.1148/rg.265045206 (Pubitemid 44518773)
13. A. Orlacchio O. Schillaci L. Antonelli, et al. 2007 Solitary pulmonary nodules: morphological and metabolic characterisation by FDG-PET-MDCT Radiol Med 112 157 173 17361379 10.1007/s11547-007-0132-x 1:STN:280:DC%2BD2s3gsFKquw%3D%3D (Pubitemid 46474823)
14. S. Risum A. Loft C. Høgdall, et al. 2010 Standardized FDG uptake as a prognostic variable and as a predictor of incomplete cytoreduction in primary advanced ovarian cancer Acta Oncol 50 415 419 20698810 10.3109/0284186X.2010.500296
15. C.T. Yen C.H. Lai 2006 Positron emission tomography in gynecological cancer Semin Nucl Med 36 93 104 16356798 10.1053/j.semnuclmed.2005.08.004 (Pubitemid 41779368)
16. H. Hricak M. Chen F.V. Coakley, et al. 2000 Complex adnexal masses: detection and characterization with MR imaging - multivariate analysis Radiology 214 39 46 10644099 1:STN:280:DC%2BD3c7gs12itw%3D%3D (Pubitemid 30019867)
17. W. Ròmer N. Avril J. Dose, et al. 1997 Metabolic characterization of ovarian tumors with positron emission tomography and F-18-fluorodeoxyglucose Rofo 166 62 68 9072107 10.1055/s-2007-1015379
18. Y. Nishiyama Y. Yamamoto K. Kanenishi, et al. 2008 Monitoring the neoadjuvant therapy response in gynecological cancer patients using FDG-PET Eur J Nucl Med Mol Imaging 35 287 295 17943281 10.1007/s00259-007-0627-7
19. P.W. Grigsby B.A. Siegel F. Dehdashti 2001 Lymph node staging by positron emission tomography in patients with carcinoma of the cervix J Clin Oncol 19 3745 3749 11533097 1:STN:280:DC%2BD3MvptVCksw%3D%3D (Pubitemid 32844787)
20. N. Avril S. Sessen B. Schmalfeldt, et al. 2005 Prediction of response to neoadjuvant chemoterapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer J Clin Oncology 23 7445 7453 10.1200/JCO.2005.06.965 (Pubitemid 46291806)
21. S.J. Booth L.W. Turnbull D.R. Poole, et al. 2008 The accurate staging of ovarian cancer using 3T magnetic resonance imaging - a realistic option BJOG 115 894 901 18485169 10.1111/j.1471-0528.2008.01716.x 1:STN:280: DC%2BD1czitlaqug%3D%3D (Pubitemid 351692995)
22. Y. Liu 2009 Benign ovarian and endometrial uptake on FDG PET-CT: patterns and pitfalls Ann Nucl Med 23 107 112 19225932 10.1007/s12149-008-0227-z 1:CAS:528:DC%2BD1MXkvFKlsrY%3D